0001209191-22-019723.txt : 20220317
0001209191-22-019723.hdr.sgml : 20220317
20220317175402
ACCESSION NUMBER: 0001209191-22-019723
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220315
FILED AS OF DATE: 20220317
DATE AS OF CHANGE: 20220317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Foley Mark J
CENTRAL INDEX KEY: 0001529196
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 22750137
MAIL ADDRESS:
STREET 1: ZELTIQ AESTHETICS INC.
STREET 2: 4698 WILLOW ROAD SUITE 100
CITY: PLEASANTON
STATE: CA
ZIP: 94588
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 6157247755
MAIL ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-15
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001529196
Foley Mark J
C/O REVANCE THERAPEUTICS, INC.
1222 DEMONBREUN STREET, SUITE 2000
NASHVILLE
TN
37203
1
1
0
0
Chief Executive Officer
Common Stock
2022-03-15
4
F
0
3304
15.79
D
765761
D
Common Stock
110913
I
See footnote
Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 40,715 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.
/s/ Terri McDowell, Attorney-in-Fact
2022-03-17